Cargando…
A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model
BACKGROUND: Conventional immunotherapy for glioma is not only expensive but also demonstrates less-than-desired clinical efficacy. In this study, we evaluated the immunotherapeutic efficacy of a tumor cell lysate-based hybrid glioma vaccine developed using a molecular-based approach. METHODS: First,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438187/ https://www.ncbi.nlm.nih.gov/pubmed/32884294 http://dx.doi.org/10.2147/OTT.S259516 |
_version_ | 1783572753095327744 |
---|---|
author | Li, Xin-Long Zeng, Shan He, Hai-Ping Zeng, Xu Peng, Li-Lei Chen, Li-Gang |
author_facet | Li, Xin-Long Zeng, Shan He, Hai-Ping Zeng, Xu Peng, Li-Lei Chen, Li-Gang |
author_sort | Li, Xin-Long |
collection | PubMed |
description | BACKGROUND: Conventional immunotherapy for glioma is not only expensive but also demonstrates less-than-desired clinical efficacy. In this study, we evaluated the immunotherapeutic efficacy of a tumor cell lysate-based hybrid glioma vaccine developed using a molecular-based approach. METHODS: First, the ability of the autologous (9L-cell lysate) and allogeneic (C6-cell lysate) vaccines against glioma, individually and in combination, to activate Fischer344 rat dendritic cells (DCs) was determined. Next, the activated DCs were co-cultured with T lymphocytes and screened for the optimal DC-to-T-cell ratio. The in vitro efficacy of the DC/T-cell vaccine formulations subjected to different immunogen treatments and co-cultured with glioma cells was evaluated based on glioma cell viability and monocyte chemoattractant protein (MCP)-2 and interferon (IFN)-γ secretion. Subsequently, the efficacy of the 9L + C6 hybrid vaccine was evaluated in 32 glioma rat models, randomly allocated to the following five treatment groups: blank control, tumor, vaccine treatment, thymosin treatment, and vaccine + thymosin treatment (combined treatment). Changes in survival duration, intracranial tumor volume, peripheral blood immune-cell (CD4+ T, CD8+ T, and natural killer [NK] cell) count, and serum cytokine (interleukin [IL]-2, IL-10) levels were assessed in these groups. RESULTS: The hybrid vaccine demonstrated the highest glioma cell apoptosis and the lowest cell viability and promoted MCP-2 and IFN-γ secretion in vitro. The vaccine treatment and combined treatment groups demonstrated longer survival duration, lower intracranial tumor volume, and higher immune cell glioma tissue infiltration and IL-2 secretion than the untreated tumor group, indicating the vaccine’s good in vivo efficacy. Thymosin treatment had minimal effect in enhancing anti-glioma immunity. CONCLUSION: We demonstrated the feasibility of combining autologous and allogeneic tumor cell lysates to stimulate specific host cell immune response against glioma cells. The good clinical efficacy of our developed glioma hybrid vaccine in rat models suggests its potential clinical application. |
format | Online Article Text |
id | pubmed-7438187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-74381872020-09-02 A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model Li, Xin-Long Zeng, Shan He, Hai-Ping Zeng, Xu Peng, Li-Lei Chen, Li-Gang Onco Targets Ther Original Research BACKGROUND: Conventional immunotherapy for glioma is not only expensive but also demonstrates less-than-desired clinical efficacy. In this study, we evaluated the immunotherapeutic efficacy of a tumor cell lysate-based hybrid glioma vaccine developed using a molecular-based approach. METHODS: First, the ability of the autologous (9L-cell lysate) and allogeneic (C6-cell lysate) vaccines against glioma, individually and in combination, to activate Fischer344 rat dendritic cells (DCs) was determined. Next, the activated DCs were co-cultured with T lymphocytes and screened for the optimal DC-to-T-cell ratio. The in vitro efficacy of the DC/T-cell vaccine formulations subjected to different immunogen treatments and co-cultured with glioma cells was evaluated based on glioma cell viability and monocyte chemoattractant protein (MCP)-2 and interferon (IFN)-γ secretion. Subsequently, the efficacy of the 9L + C6 hybrid vaccine was evaluated in 32 glioma rat models, randomly allocated to the following five treatment groups: blank control, tumor, vaccine treatment, thymosin treatment, and vaccine + thymosin treatment (combined treatment). Changes in survival duration, intracranial tumor volume, peripheral blood immune-cell (CD4+ T, CD8+ T, and natural killer [NK] cell) count, and serum cytokine (interleukin [IL]-2, IL-10) levels were assessed in these groups. RESULTS: The hybrid vaccine demonstrated the highest glioma cell apoptosis and the lowest cell viability and promoted MCP-2 and IFN-γ secretion in vitro. The vaccine treatment and combined treatment groups demonstrated longer survival duration, lower intracranial tumor volume, and higher immune cell glioma tissue infiltration and IL-2 secretion than the untreated tumor group, indicating the vaccine’s good in vivo efficacy. Thymosin treatment had minimal effect in enhancing anti-glioma immunity. CONCLUSION: We demonstrated the feasibility of combining autologous and allogeneic tumor cell lysates to stimulate specific host cell immune response against glioma cells. The good clinical efficacy of our developed glioma hybrid vaccine in rat models suggests its potential clinical application. Dove 2020-08-14 /pmc/articles/PMC7438187/ /pubmed/32884294 http://dx.doi.org/10.2147/OTT.S259516 Text en © 2020 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Li, Xin-Long Zeng, Shan He, Hai-Ping Zeng, Xu Peng, Li-Lei Chen, Li-Gang A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model |
title | A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model |
title_full | A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model |
title_fullStr | A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model |
title_full_unstemmed | A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model |
title_short | A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model |
title_sort | hybrid glioma tumor cell lysate immunotherapy vaccine demonstrates good clinical efficacy in the rat model |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438187/ https://www.ncbi.nlm.nih.gov/pubmed/32884294 http://dx.doi.org/10.2147/OTT.S259516 |
work_keys_str_mv | AT lixinlong ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT zengshan ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT hehaiping ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT zengxu ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT penglilei ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT chenligang ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT lixinlong hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT zengshan hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT hehaiping hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT zengxu hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT penglilei hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel AT chenligang hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel |